This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice. Learning objectives Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other diseases Get familiar with the role of non-invasive tests for risk stratification in MASLD, their pro- and cons, and how and in whom to use them for screening/case finding Get a detailed understanding of HCC risk and risk stratification in MASLD and the surveillance strategies to implement This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and Novo Nordisk. Boehringer Ingelheim and Novo Nordisk have had no input in the selection and creation of this programme.